Format

Send to

Choose Destination
Hum Vaccin Immunother. 2013 Nov;9(11):2427-33. Epub 2013 Jul 9.

Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma.

Author information

1
Division of Clinical Sciences; St George's University of London; Tooting, London, UK.

Abstract

BACKGROUND:

The long-term prognosis of patients with stage IV AJCC melanoma is extremely poor. We have previously published short-term clinical outcome and immunological responses to a heat killed Mycobacterium vaccae-based vaccine.

RESULTS:

In this study we report on a better than expected long-term survival (3-y DSS 29·6%, 5-y, and 7-y DSS both 23·9%) relative to historical controls in the patients who received the vaccine in these trials, published in 1999 and 2003. Although the complete or partial response was only 10%, it was the remarkable response to other interventions upon relapse, such as surgery and radiotherapy followed by stable disease that was previously unexpected.

METHODS:

We reviewed the outcome of 72 patients who were treated with M. vaccae for metastatic melanoma between January 1996 and July 2004.

CONCLUSION:

Given this remarkable outcome in stage IV metastatic melanoma and its lack of toxicity we propose that this would make a promising candidate for randomized trials for stage III fully resected melanoma.

KEYWORDS:

long-term survival; mycobacterial vaccine; stage IV melanoma

PMID:
23863507
PMCID:
PMC3981853
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center